Atea Pharmaceuticals, Inc. Share Price & Technical Analysis
AVIR · $4.24 (+1.19%)
Healthcare / Biotechnology
$4.24
+1.19%
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company a…
Price chart
Seasonality
May has 2 positive and 1 negative years (last 5 years shown)
-20% return in May, 7% avg return in past 3 year May month.
28% return in 2026, 1% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 17% | 12% | 17% | 2% | -20% | – | – | – | – | – | – | – | 28% |
| 25 | -9% | 0% | 0% | 0% | 0% | 20% | 0% | -6% | -12% | 10% | -3% | 16% | 17% |
| 24 | 40% | 13% | -7% | -7% | 0% | -11% | 15% | 0% | -13% | -6% | 3% | -3% | 24% |
| 23 | -6% | -24% | 0% | 0% | 21% | -7% | -8% | -3% | -12% | 7% | -6% | 0% | -39% |
| 22 | -24% | -12% | 3% | -18% | 34% | -10% | 15% | -9% | -23% | 5% | -24% | 2% | -60% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$427.74M
P/E ratio
—
52W high
$6.45
52W low
$2.78
Volume
3,99,331
Beta
0.38
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Atea Pharmaceuticals, Inc. share price today?
- Atea Pharmaceuticals, Inc. (AVIR) last traded around $4.24 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AVIR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AVIR. Download the app for real-time alerts.
- How can I analyze Atea Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.